4.7 Article

Detection of Resistance to Beta-Lactamase Inhibitors in Strains with CTX-M Beta-Lactamases: a Multicenter External Proficiency Study Using a Well-Defined Collection of Escherichia coli Strains

Journal

JOURNAL OF CLINICAL MICROBIOLOGY
Volume 52, Issue 1, Pages 122-129

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.02340-13

Keywords

-

Categories

Funding

  1. European Commission [HEALTH-2009-241476]
  2. European Commission
  3. Ministerio de Economia y Competitividad, Instituto de Salud Carlos III, Spain [PI08/0624, PI12/00567, PI08/0397, PI11/01117]
  4. European Development Regional Fund A way to achieve Europe (EDRF)
  5. Spanish Network for Research in Infectious Diseases [REIPI RD12/0015]

Ask authors/readers for more resources

Under the auspices of the Spanish Society for Infectious Diseases and Clinical Microbiology Quality Control program, 14 Escherichia coli strains masked as blood culture isolates were sent to 68 clinical microbiology laboratories for antimicrobial susceptibility testing to beta-lactam antibiotics. This collection included three control strains (E. coli ATCC 25922, an IRT-2 producer, and a CMY-2 producer), six isogenic strains with or without the OmpF porin and expressing CTX-M beta-lactamases (CTX-M-1, CTX-M-15, and CTX-M-14), one strain carrying a double mechanism for beta-lactam resistance (i.e., carrying CTX-M-15 and OXA-1 enzymes), and four strains carrying CTX-M variants with different levels of resistance to beta-lactams and beta-lactam-beta-lactamase inhibitor (BLBLI) combinations. The main objective of the study was to ascertain how these variants with reduced susceptibilities to BLBLIs are identified in clinical microbiology laboratories. CTX-M variants with high resistance to BLBLIs were mainly identified as inhibitor-resistant TEM (IRT) enzymes (68.0%); however, isogenic CTX-M mutant strains with reduced susceptibilities to BLBLIs and cephalosporins were mainly associated with extended-spectrum beta-lactamase production alone (51 to 80%) or in combination with other mechanisms (14 to 31%). Concerning all beta-lactams tested, the overall interpretative discrepancy rate was 11.5%, of which 38.1% were the consequence of postreading changes in the clinical categories when a resistance mechanism was inferred. Therefore, failure to recognize these complex phenotypes might contribute to an explanation of their apparent absence in the clinical setting and might lead to inadequate drug treatment selection. A proposal for improving recognition is to adhere strictly to the current CLSI or EUCAST guidelines for detecting reduced susceptibility to BLBLI combinations, without any interpretative modification.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available